From: Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMS
 | Embryonal RMS n (%) |
---|---|
Sex | Â |
  Male | 11 (58) |
  Female | 8 (42) |
Age (years) | Â |
  < 10 | 14 (74) |
  ≥ 10 | 5 (26) |
Localisation | Â |
  Orbit-genitourinary tract-head and neck$ | 9 (47) |
  Cranial paramenigeal-extremity-other$$ | 10 (53) |
Tumor volume | Â |
  < 5 cm | 7 (37) |
  ≥ 5 cm | 12 (63) |
IRS stage | Â |
  I | 2 (10) |
  II | 3 (16) |
  III | 11 (58) |
  IV | 3 (16) |
Metastasis | Â |
  No | 16 (84) |
  Yes | 3 (16) |
Recurrence | Â |
  No | 12 (63) |
  Yes | 7 (37) |
Outcome | Â |
  Alive | 13 (68) |
  DOD | 6 (32) |
Expression of markers | Â |
  EZH2 (positive cells/microscopic field) | 40 (range 29-44) |
  Ki67 (positive cells/microscopic field) | 20 (range 17-29) |